human
cancer
vaccin
vaccin
tradit
use
gener
protect
infecti
pathogen
use
success
control
case
smallpox
erad
infecti
agent
diseas
target
vaccin
main
rapid
onset
lifethreaten
consequ
persist
infect
also
result
develop
lifethreaten
diseas
longer
time
frame
sever
human
cancer
caus
infecti
agent
overal
cancer
estim
constitut
global
cancer
burden
recent
vaccin
prevent
infect
oncogen
human
papillomavirus
approv
use
us
feder
drug
administr
fda
much
public
vaccin
cervic
cancer
cancer
vaccin
howev
realli
antivir
vaccin
similar
convent
prophylact
vaccin
ie
induc
host
neutralis
antibodi
respons
prevent
infect
vaccin
discuss
issu
differ
mode
oper
sever
import
aspect
cancer
vaccin
aim
treat
establish
diseas
rather
prevent
achiev
main
induct
strong
cell
respons
although
cancer
vaccin
contain
antigen
capabl
induc
antibodi
cell
respons
prophylact
vaccin
gener
given
childhood
provid
longliv
immun
contrast
cancer
tend
diseas
age
popul
cancer
vaccin
differ
target
popul
present
durat
immun
unknown
comparison
two
type
vaccin
shown
tabl
howev
mani
similar
convent
prophylact
therapeut
cancer
vaccin
least
deliveri
technolog
use
tradit
prophylact
vaccin
use
attenu
kill
pathogen
howev
approach
ineffect
deal
outbreak
caus
new
pathogen
sarscov
avian
influenza
increasingli
modern
vaccin
whether
prophylact
therapeut
focu
subunit
immunogen
form
protein
peptid
nucleic
acid
requir
deliveri
either
conjunct
adjuv
associ
vector
system
adjuv
properti
eg
recombin
virus
heat
shock
protein
concert
develop
vaccinolog
tremend
advanc
understand
immunolog
cancer
cell
biolog
lead
intens
research
develop
cancer
vaccin
field
pois
key
junctur
sever
candid
vaccin
progress
phase
iii
clinic
trial
dendrit
cell
base
vaccin
prostat
cancer
dendreon
corpor
given
fasttrack
statu
licens
fda
articl
issu
provid
wide
coverag
field
describ
relev
vaccin
host
paramet
need
consid
cancer
vaccin
design
dr
tabi
man
look
detail
challeng
involv
cancer
vaccin
develop
particularli
focuss
tumour
cell
biolog
tumour
escap
immun
system
also
provid
summari
current
cancer
vaccin
commerci
develop
review
differ
approach
taken
follow
three
articl
focuss
individu
vaccin
approach
harrop
et
al
review
use
recombin
viral
vector
cancer
vaccin
describ
develop
candid
vaccin
clinic
test
van
der
burg
colleagu
describ
rational
behind
use
synthet
peptid
vaccin
key
paramet
involv
maximis
efficaci
three
articl
detail
host
environ
also
influenc
success
cancer
vaccin
slettenaar
wilson
review
chemokin
influenc
migrat
function
immun
effector
cell
bett
et
al
review
effector
cell
also
regul
subset
natur
occur
regulatori
cell
treg
describ
accumul
evid
mice
human
treg
detriment
anticanc
respons
manipul
treg
benefici
cancer
vaccin
strategi
final
nowak
colleagu
review
anoth
system
improv
perform
cancer
vaccin
use
combin
standard
chemotherapi
treatment
despit
recent
research
develop
provid
impetu
new
clinic
trial
field
human
cancer
vaccin
remain
challeng
recent
high
profil
set
back
compani
work
therapeut
vaccin
melanoma
cancervax
kidney
antigen
pancreat
cancer
therion
perceiv
neg
effect
field
unfair
cancer
vaccin
compani
use
differ
specialis
technolog
vaccin
target
differ
cancer
major
challeng
remain
obtain
signific
clinic
effect
patient
advanc
diseas
fail
convent
therapi
convent
wisdom
combin
advanc
diseas
chemo
radiotherapeut
treatment
would
constrain
develop
immun
respons
follow
vaccin
howev
becom
increasingli
appreci
standard
treatment
cancer
chemotherapi
radiat
therapi
posit
immun
effect
direct
indirect
mechan
excit
clinic
implic
first
test
mani
cancer
vaccin
may
suboptim
trial
carri
patient
fail
standard
treatment
second
may
benefici
combin
treatment
synergist
effect
benefit
allow
vaccin
trial
piggyback
onto
larg
scale
trial
chemotherapeut
radiotherapeut
regim
futur
prospect
cancer
vaccin
success
develop
monoclon
antibodi
licens
cancer
therapeut
particularli
lymphoid
cancer
provid
key
pointer
firstli
long
lag
period
discoveri
therapeut
success
late
secondli
increment
improv
technolog
lead
greater
efficaci
thirdli
given
target
anticanc
effect
could
mediat
multipl
mechan
includ
nonimmunolog
one
fourthli
realis
larger
dose
antibodi
need
efficaci
cancer
vaccin
potenti
target
much
broader
rang
cancer
monoclon
antibodi
patienc
fortitud
need
potenti
realis
